TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16879931

Group type: EXPERIMENTAL
Intervention: Gabapentin 2400 mg/day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Gabapentin 3200 mg/day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cocaine (0, 12, 25, 50 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Gabapentin 0 mg/day (placebo)
Number of subjects: 6
Study: 15319143

Group type: EXPERIMENTAL
Intervention: 300 mg Mg++ daily (group A)
Number of subjects: 110

Group type: COMPARATOR
Intervention: No supplement (group B)
Number of subjects: 110
Study: 11466190

Group type: EXPERIMENTAL
Intervention: Photopheresis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9580800

Group type: EXPERIMENTAL
Intervention: metronidazole 2%
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: permethrin 1%
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: sublimed sulphur 10%
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: lindane 1%
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: crotamiton 10%
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: benzyl benzoate (BB) 10%
Number of subjects: 34
Study: 7923309

Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg twice daily (increased to 20 mg twice daily if necessary)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 74
Study: 3044508

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of cholestyramine and bezafibrate
Number of subjects: 18
Study: 31974533

Group type: EXPERIMENTAL
Intervention: Riociguat treatment after 5 months
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Riociguat treatment after 11.2 months
Number of subjects: 51
Study: 29228517

Group type: COMPARATOR
Intervention: Face-to-face CBT-BN
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Internet-based CBT-BN
Number of subjects: 179
Study: 28126491

Group type: EXPERIMENTAL
Intervention: Non-nutritive sweetened beverage (NSB; sucralose; 4 g)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sugar-sweetened beverage (SSB; sucrose; 31 g)
Number of subjects: 21
Study: 26006702

Group type: EXPERIMENTAL
Intervention: 10 mg oral immediate-release onapristone after an overnight fast
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg oral immediate-release onapristone within 30 min of a high-fat, high-calorie meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg oral immediate-release onapristone
Number of subjects: 12
Study: 23663191

Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 34

Group type: COMPARATOR
Intervention: Stay active (Control)
Number of subjects: 34
Study: 20367670

Group type: EXPERIMENTAL
Intervention: Pulsed dye laser therapy after 60-90 min ALA application
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 44
Study: 18419537

Group type: EXPERIMENTAL
Intervention: Efavirenz-based regimens with 2 or 3 NRTIs
Number of subjects: 0
Study: 16308351

Group type: EXPERIMENTAL
Intervention: Intravenous isoproterenol (isoprenaline): 6, 12 and 24 ng (kg fat‐free mass)‐1 min‐1
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (vitamin C; 0.04 g (kg fat‐free mass)‐1)
Number of subjects: 39
Study: 14515011

Group type: EXPERIMENTAL
Intervention: High-intensity exercise (treadmill running at 60, 75, 90, and 100% VO(2 max))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control trial (resting)
Number of subjects: 0
Study: 11185026

Group type: EXPERIMENTAL
Intervention: New tailored walking campaigns
Number of subjects: 181

Group type: COMPARATOR
Intervention: English Health Education Authority (HEA) 'Active for Life' campaign
Number of subjects: 181
Study: 9088775

Group type: EXPERIMENTAL
Intervention: Insulin Lispro (LP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Human Insulin (H)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Porcine Insulin (P)
Number of subjects: 12
Study: 8462534

Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac, 100 mg
Number of subjects: 169

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 169
Study: 3517396

Group type: EXPERIMENTAL
Intervention: Intervention group (geriatric consultation team)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group (no geriatric consultation team)
Number of subjects: 185
Study: 29905973

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg/d plus sham vibration 10 min/d (n=20)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo plus vibration 10 min/d (n=20)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg/d plus vibration 10 min/d (n=21)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg/d after 12-month extension
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: All groups after 12-month extension
Number of subjects: 61
Study: 26250786

Group type: EXPERIMENTAL
Intervention: White Diet
Number of subjects: 226

Group type: COMPARATOR
Intervention: Clear-fluid diet
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Split-dose regimen
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Day-before regimen
Number of subjects: 226
Study: 25207759

Group type: EXPERIMENTAL
Intervention: Temperature-modulated photodynamic therapy (PDT) with 20% ALA and 10 J/cm, 417-nm blue light, heated during incubation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control side (not heated)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Temperature-modulated PDT
Number of subjects: 20
Study: 22776824

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 1 mg
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 2.5 mg
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (all doses)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 282
Study: 20055989

Group type: EXPERIMENTAL
Intervention: Lower tidal volume (6 ml/kg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional tidal volume (10 ml/kg)
Number of subjects: 150
Study: 17849474

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 65

Group type: COMPARATOR
Intervention: Transfusion
Number of subjects: 65
Study: 15699275

Group type: EXPERIMENTAL
Intervention: Exercise training (ET)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (inactive)
Number of subjects: 45
Study: 12745558

Group type: EXPERIMENTAL
Intervention: 250 mg vitamin C twice daily until 34 weeks' gestation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (matching)
Number of subjects: 0
Study: 10784581

Group type: EXPERIMENTAL
Intervention: Colonoscopy screening at 3-year intervals
Number of subjects: 252

Group type: COMPARATOR
Intervention: No screening (control)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Colonoscopy screening in mutation-positive subjects
Number of subjects: 252

Group type: COMPARATOR
Intervention: No screening in mutation-positive subjects (control)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Colonoscopy screening
Number of subjects: 252
Study: 8810613

Group type: EXPERIMENTAL
Intervention: AutoSet nCPAP titration
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Manual titration
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional fixed-pressure nCPAP
Number of subjects: 21

Group type: COMPARATOR
Intervention: Diagnostic night
Number of subjects: 21
Study: 1448529

Group type: EXPERIMENTAL
Intervention: Rapid expansion (every day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Slow expansion (every week)
Number of subjects: 23
Study: 4020121

Group type: EXPERIMENTAL
Intervention: timolol (10 mg/day, n = 14)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: methyldopa (250 mg/day, n = 16)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (25 mg/day) and amiloride (2.5 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: timolol (n = 7)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: methyldopa (n = 16)
Number of subjects: 30
Study: 30884215

Group type: EXPERIMENTAL
Intervention: Mutual Information (MI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Variation of Information (VI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Window size of at least 120 s
Number of subjects: 0
Study: 28846562

Group type: EXPERIMENTAL
Intervention: Real-time BandCizer™-iPad feedback on contraction time
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 40
Study: 26729245

Group type: EXPERIMENTAL
Intervention: Systemic therapy (hydroxychloroquine, methotrexate, mycophenolate mofetil, prednisolone) in addition to standard topical therapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Topical therapy plus a short course of prednisolone given orally
Number of subjects: 96
Study: 25246739

Group type: EXPERIMENTAL
Intervention: ICO group using one icodextrin‐containing and two glucose‐containing dialysates (n=41)
Number of subjects: 80

Group type: COMPARATOR
Intervention: GLU group continuously using four glucose‐containing dialysates (n=39)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ICO group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 22475108

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Standard surgical debridement and sequestrectomy
Number of subjects: 7
Study: 20150905

Group type: EXPERIMENTAL
Intervention: Equoral
Number of subjects: 99

Group type: COMPARATOR
Intervention: Neoral
Number of subjects: 99
Study: 17914310

Group type: EXPERIMENTAL
Intervention: Fusidic acid (4 mg/mL) and heparin (10 IU/mL) lock
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no fusidic acid-heparin lock)
Number of subjects: 103
Study: 16182311

Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg i.v. eight hourly
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g six hourly
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 11583670

Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Laser in situ keratomileusis (LASIK)
Number of subjects: 45
Study: 9728918

Group type: EXPERIMENTAL
Intervention: Functional MRI testing of a cortical region straddling the right lingual sulcus for building perception.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experiments discounting alternative explanations for the behavior of the identified site.
Number of subjects: 0
Study: 7976758

Group type: EXPERIMENTAL
Intervention: Laser-assisted liposuction
Number of subjects: 51
Study: 3592003

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 29632995

Group type: EXPERIMENTAL
Intervention: Trimodulin (42 mg IgM/kg/day)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Trimodulin
Number of subjects: 160
Study: 27537999

Group type: EXPERIMENTAL
Intervention: Calcipotriene (Cal) 0.005% plus betamethasone dipropionate (BD) 0.064% aerosol foam
Number of subjects: 426

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 426
Study: 24122814

Group type: EXPERIMENTAL
Intervention: CSL112 (3.4 g or 6.8 g, administered intravenously once or twice weekly)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CSL112 (multiple infusions)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (administered intravenously)
Number of subjects: 36
Study: 23286932

Group type: EXPERIMENTAL
Intervention: In-plane technique
Number of subjects: 81

Group type: COMPARATOR
Intervention: Out-of-plane technique
Number of subjects: 81
Study: 21219987

Group type: EXPERIMENTAL
Intervention: 15 μg of haemagglutinin (HA) of each of three influenza strains on days 0 and 14
Number of subjects: 1349

Group type: EXPERIMENTAL
Intervention: 30 μg of haemagglutinin (HA) on day 0 and saline placebo on day 14
Number of subjects: 1349

Group type: COMPARATOR
Intervention: Placebo on days 0 and 14
Number of subjects: 1349

Group type: EXPERIMENTAL
Intervention: Both vaccine dose groups
Number of subjects: 1349
Study: 19346228

Group type: EXPERIMENTAL
Intervention: Copeptin
Number of subjects: 224

Group type: COMPARATOR
Intervention: BNP
Number of subjects: 224

Group type: COMPARATOR
Intervention: NT-proBNP
Number of subjects: 224
Study: 17001147

Group type: EXPERIMENTAL
Intervention: SPETA (Standardized Physical Examination Teaching Associates)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Physician faculty
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: SPETA
Number of subjects: 144
Study: 15351765

Group type: EXPERIMENTAL
Intervention: Cognitive enhancement therapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Enriched supportive therapy
Number of subjects: 121
Study: 10756576

Group type: EXPERIMENTAL
Intervention: Paraffin gauze
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Polyurethane foam
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Polyethane film
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Polyurethane film
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study: 9266871

Group type: EXPERIMENTAL
Intervention: Two months of inpatient rehabilitation followed by 4 months of outpatient supervision
Number of subjects: 84
Study: 8336989

Group type: EXPERIMENTAL
Intervention: Bamiphylline
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 6437286

Group type: EXPERIMENTAL
Intervention: Diazepam (0.29 mg/kg, iv) + Physostigmine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Morphine (0.21 mg/kg, iv) + Physostigmine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Physostigmine alone (3 mg, iv)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30482720

Group type: COMPARATOR
Intervention: Saline (P0)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phenylephrine 25 (P25)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phenylephrine 50 (P50)
Number of subjects: 60
Study: 29095051

Group type: EXPERIMENTAL
Intervention: Obese patients (BMI ≥ 30 kg/m2)
Number of subjects: 2410

Group type: EXPERIMENTAL
Intervention: High waist circumference (≥102 cm for men, ≥88 cm for women)
Number of subjects: 2410

Group type: EXPERIMENTAL
Intervention: Increment of 5 kg/m2 in body mass index
Number of subjects: 2410

Group type: EXPERIMENTAL
Intervention: Overall population (both obese and non-obese)
Number of subjects: 2410
Study: 27323608

Group type: EXPERIMENTAL
Intervention: Jiangzhi Xiaoban Tablet (JXT), 0.45 g/tablet, 4 tablets each time, 3 times per day for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simvastatin Tablet, 20 mg/tablet, 1 tablet each time, once per evening for 8 weeks
Number of subjects: 60
Study: 24497220

Group type: EXPERIMENTAL
Intervention: Brotizolam 0.25 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg/day
Number of subjects: 12
Study: 22515899

Group type: EXPERIMENTAL
Intervention: Manual compaction (MC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ultrasonic activation for 1 second (1 sec-UC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ultrasonic activation for 5 seconds (5 sec-UC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ultrasonic activation for 10 seconds (10 sec-UC)
Number of subjects: 48
Study: 20404229

Group type: EXPERIMENTAL
Intervention: e-visit platform
Number of subjects: 151

Group type: COMPARATOR
Intervention: office visit
Number of subjects: 151
Study: 17413465

Group type: EXPERIMENTAL
Intervention: Immobilization of the cervical spine in a rigid collar followed by active mobilization
Number of subjects: 458

Group type: COMPARATOR
Intervention: Advice to 'act-as-usual'
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Active mobilization program (Mechanical Diagnosis and Therapy)
Number of subjects: 458
Study: 16720131

Group type: EXPERIMENTAL
Intervention: Diet and exercise group (restrict energy intake by 500 kcal/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet and exercise group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (maintain usual dietary intake)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet and exercise group and Control group
Number of subjects: 0
Study: 14723508

Group type: EXPERIMENTAL
Intervention: Time-frequency algorithm for wheeze detection
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Bronchodilator drug (Terbutaline)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Clinical auscultation
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Time-frequency wheeze parameters
Number of subjects: 31
Study: 11028835

Group type: EXPERIMENTAL
Intervention: 5-HT3 receptor antagonists (specifically 2 mg intravenous tropisetron)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychological changes (depressive disorders)
Number of subjects: 0
Study: 8708247

Group type: EXPERIMENTAL
Intervention: Peer-driven injury prevention programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health care professional-led prevention presentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 1622045

Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP) 0.3 microgram/kg infusion over 15 min after cardiopulmonary bypass
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo infusion over 15 min after cardiopulmonary bypass
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 6090539

Group type: EXPERIMENTAL
Intervention: Topical acyclovir therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 31928784

Group type: EXPERIMENTAL
Intervention: Italian version of the SIPAT
Number of subjects: 118
Study: 31615480

Group type: EXPERIMENTAL
Intervention: HABIT intervention delivered by community health workers (CHWs) with tailored text messages on hydroxyurea adherence.
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual clinical care plus education handouts (Control group).
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: HABIT intervention
Number of subjects: 104
Study: 27839892

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist's intervention (education provided to patients and caregivers)
Number of subjects: 178
Study: 25358874

Group type: COMPARATOR
Intervention: Valsartan alone (Group 1)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Valsartan and Clopidogrel (Group 2)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Valsartan and Leflunomide (Group 3)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Valsartan, Clopidogrel, and Leflunomide (Group 4)
Number of subjects: 168
Study: 23710796

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (10 therapy sessions over 3 months, followed by 4 maintenance sessions over 6 months)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 480
Study: 22025630

Group type: EXPERIMENTAL
Intervention: Bedtime dosing of at least one BP-lowering medication
Number of subjects: 661
Study: 19794973

Group type: EXPERIMENTAL
Intervention: Short-duration exercise (treadmill test)
Number of subjects: 100
Study: 17707980

Group type: EXPERIMENTAL
Intervention: Butter (B)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Low TFA margarine (LT)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Regular margarine (RM)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 11
Study: 15339577

Group type: EXPERIMENTAL
Intervention: Fuzheng Huayu Capsule (FZHY Capsule)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Heluo Shugan Capsule (Control)
Number of subjects: 216
Study: 10898841

Group type: EXPERIMENTAL
Intervention: Implant-supported overdentures on a transmandibular implant system (n = 21)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Implant-mucosa-supported overdentures on 2 IMZ implants (n = 20)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional complete dentures (n = 14)
Number of subjects: 55
Study: 9151586

Group type: EXPERIMENTAL
Intervention: Bioceram sapphire implants with overdentures
Number of subjects: 86
Study: 1358044

Group type: EXPERIMENTAL
Intervention: Nebivolol 1 mg/day for 48 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nebivolol 2.5 mg/day for 72 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nebivolol 2.5 mg for one week then 5 mg for 5 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 12
Study: 6382887

Group type: EXPERIMENTAL
Intervention: Cimetidine treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 33
Study: 30502314

Group type: EXPERIMENTAL
Intervention: Infants of women with HDP
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control group (infants of women without HDP)
Number of subjects: 221
Study: 29920323

Group type: EXPERIMENTAL
Intervention: 4 g high molecular weight oat β-glucan
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control breakfast
Number of subjects: 33
Study: 28040073

Group type: EXPERIMENTAL
Intervention: Volar locking plate fixation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (Volar locking plate fixation)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (Intramedullary nailing)
Number of subjects: 28
Study: 23852152

Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg) associated with double-dose clopidogrel (150 mg)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Double-dose clopidogrel alone
Number of subjects: 76
Study: 21048432

Group type: EXPERIMENTAL
Intervention: Mixed model for cholesterol-reducing treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: General linear model for cholesterol-reducing treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed model for sleeplessness treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: General linear model for sleeplessness treatments
Number of subjects: 0